<DOC>
	<DOC>NCT02130310</DOC>
	<brief_summary>The primary objective is to evaluate the clinical benefit of CureXcell® as adjunct to Standard of Care in the treatment of Chronic Venous Leg Ulcers. CureXcell® is a cell based therapy, containing activated homologous white blood cells prepared from donated healthy whole blood. A total of 252 patients will be randomized to receive either CureXcell® or Placebo.</brief_summary>
	<brief_title>Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Ankle Brachial Pressure Index (ABI) ≥ 0.80 Venous insufficiency confirmed by duplex Doppler ultrasound Presence of a venous leg ulcer, unresponsive to Standard of Care treatment for at least 4 weeks and between ≥ 1 cm2 and ≤ 17.1 cm2 at screening; and between ≥ 1 cm2 and ≤ 12cm2 at the Baseline Visit Target Ulcer has decreased &gt;30% in size from Screening to Baseline Documented history of osteomyelitis at the Target Ulcer location within 6 months preceding the Baseline Visit. Patients who are unable to tolerate multilayer compression therapy. Ulcer, which in the opinion of the Investigator is suspicious for cancer. Any malignancy within the past 5 years, excluding successfully treated basal cell carcinoma or squamous cell carcinoma without evidence of metastases. History of radiation at the Target Ulcer site in previous 12 months prior to Baseline Visit. Patients with clinically significant claudication Current sepsis Patients with known history of significantly compromised immunity for any reason including radiation therapy, chemotherapy or HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic ulcers</keyword>
	<keyword>Venous ulcers</keyword>
</DOC>